Sinclair Pharma PLC Silhouette Instalift wins NewBeauty Magazine Award
23 May 2018 - 5:00PM
RNS Non-Regulatory
TIDMSPH
Sinclair Pharma PLC
23 May 2018
FDA CLEARED SILHOUETTE INSTALIFT(R) WINS NEWBEAUTY MAGAZINE
BEAUTY CHOICE AWARD
Industry Breakthrough That Has the Power to Change Lives
London, 23 May 2018 Sinclair Pharma plc (AIM:SPH.L) ("Sinclair"
or the "Group"), the international aesthetics company, is pleased
to announce that its revolutionary facial rejuvenation technology,
Silhouette InstaLift (R), has been named a 2018 NewBeauty Magazine
Annual Beauty Choice Awards Winner in the category of "Industry
Breakthroughs That Have the Power to Change Lives."
The Beauty Choice Awards, announced in the Spring/Summer 2018
issue of NewBeauty Magazine, showcase the "Best Beauty Products and
Treatments in the World." Winners are selected by industry experts,
NewBeauty editors and readers. Silhouette InstaLift (R) was
recognized for its ability to immediately lift and add volume to
the midface while maintaining a natural, healthy look and helping
to establish and enhance a youthful facial shape, giving patients a
more attractive facelift alternative to invasive surgery.
Silhouette InstaLift(R) stands among a renowned list of products
and treatments to have received this prestigious award.
"My patients don't want to look over-done, so they love
Silhouette InstaLift(R) because it helps increase volume while
restoring shapeliness to the mid-face and cheek area and still
appears natural," said New York Dermatologist, Marina Peredo, MD.
"Silhouette InstaLift (R) fulfills a growing need in the explosive
skin rejuvenation category and is a game-changing solution for
patients who don't want surgery."
"We are honored to earn recognition for our industry-leading
treatment from NewBeauty, a publication recognized as a leading
resource on aesthetics for consumers and patients," said Mike
Zuccala, Vice President, Sales & Marketing, Sinclair USA.
"Silhouette InstaLift (R) represents the next generation in
non-invasive facial procedures. It is the first and only FDA
cleared, minimally invasive procedure that lifts, volumizes, and
helps establish a more youthful facial shape with minimal downtime
and an excellent safety profile. This award further demonstrates
our committment to bringing innovative aesthetic treatments to
physicians and their patients."
For further information please contact:
Sinclair Pharma plc Tel: +44 (0) 20 7467
6920
Chris Spooner
Alan Olby
Andy Crane
Media enquiries
FTI Consulting Tel: +44 (0) 203 727
1000
Ben Atwell
Brett Pollard
Stephanie Cuthbert
Notes to Editors:
About Sinclair Pharma plc - www.sinclairpharma.com
Sinclair Pharma plc is an international company operating in the
fast growth, high gross margin, global aesthetics market. Sinclair
has built a strong portfolio of differentiated, complementary
aesthetics technologies, which are experiencing significant growth,
targeting unmet clinical needs for effective, high quality, longer
duration, natural looking and minimally-invasive treatments.
Sinclair is planning entry to multiple new geographic markets and
line extension launches over the next few years. The Group has an
established sales and marketing presence in the leading EU markets
and Brazil, and a network of international distributors.
About Silhouette InstaLift
Silhouette InstaLift is a minimally-invasive, resorbable
suspension suture with bi- directional cones. The sutures lift and
reposition subdermal tissue while the bi- directional cones hold
the suture and facial skin in an elevated position. The suture and
cone material are both made of glycolide / L-lactide (PLGA) and
over time they stimulate fibroblasts for gradual collagen
maturation and are designed to reposition volume in the mid-face
with a goal of a natural-looking result.
Connect with us:
Facebook/Twitter/Instagram @InstaliftUS
#SilhouetteInstalift
"Safe Harbor" Statement under the US Private Securities
Litigation Reform Act of 1995: Some or all of the statements in
this document that relate to future plans, expectations, events,
performances and the like are forward--looking statements, as
defined in the US Private Securities Litigation Reform Act of 1995.
Actual results of events could differ materially from those
described in the forward--looking statements due to a variety of
factors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEASSAAFNPEFF
(END) Dow Jones Newswires
May 23, 2018 03:00 ET (07:00 GMT)
Sinclair Pharma (LSE:SPH)
Historical Stock Chart
From Apr 2024 to May 2024
Sinclair Pharma (LSE:SPH)
Historical Stock Chart
From May 2023 to May 2024